Drugs.com - Pharma Industry News

Nivolumab Added to Chemo Improves Response in ER+, HER2− Breast Cancer

THURSDAY, Feb. 6, 2025 -- For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer (BC), adding nivolumab to neoadjuvant chemotherapy increases...

Feb 9, 2025 - 21:45
 0
Nivolumab Added to Chemo Improves Response in ER+, HER2− Breast Cancer
THURSDAY, Feb. 6, 2025 -- For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer (BC), adding nivolumab to neoadjuvant chemotherapy increases...
Read More

Tags:

Previous Article

Weight Gain Common in Young Women After Breast Reduction Surgery

Next Article

HoLEP Double-n Technology Promising for Benign Prostatic Hyperplasia

Related Posts

Rural-Urban Differences Seen in Cardiometabolic Risk Factors, CVD

Rural-Urban Differences Seen in Cardiometabolic Risk Fa...

Apr 8, 2025  0

ACP Issues Clinical Guideline for Pharmacologic Prevention of Episodic Migraine

ACP Issues Clinical Guideline for Pharmacologic Prevent...

Feb 10, 2025  0

Real-World Study Shows Effectiveness of Ixekizumab for Psoriasis

Real-World Study Shows Effectiveness of Ixekizumab for ...

Feb 28, 2025  0